Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III - Genetic Engineering News PDF Print
Genetic Engineering NewsLead product IMA901 comprises 10 TUMAPs that immatics clams are frequently found to be over-expressed in patients suffering from renal cell carcinoma. ...immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.